Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development

Immunology

Volumn 145, Issue 4, 2015, Pages 583-596

  Marques, Rafael E ^a   Guabiraba, Rodrigo ^b   Del Sarto, Juliana L ^a   Rocha, Rebeca F ^a   Queiroz, Ana Luiza ^a   Cisalpino, Daniel ^a   Marques, Pedro E ^a   Pacca, Carolina C ^c   Fagundes, Caio T ^a   Menezes, Gustavo B ^a   Nogueira, Maurício L ^c   Souza, Danielle G ^a   Teixeira, Mauro M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UR1282   (France)

^c FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

CC chemokine receptor 5; Chemokines; Dengue virus; Inflammation; Viral replication

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; LIGAND; CCR5 PROTEIN, HUMAN; CCR5 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INFECTION RESISTANCE; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET ORGAN; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; BASE SEQUENCE; DENGUE; DENGUE VIRUS; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; VIRUS REPLICATION;

EID: 84936192693     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12476     Document Type: Article

References (62)

1. WHO. Global strategy for dengue prevention and control 2012-2020. In: Publications W, ed. WHO website (www.who.int), 2012.
2. Marques RE, Guabiraba R, Cisalpino D, Teixeira MM, Souza DG. Dengue. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2014; 6:1-104.
3. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis 2002; 2:33-42.
4. Kalayanarooj S, Vaughn DW, Nimmannitya S et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313-21.
5. Who T. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: WHO Library, 2009.
6. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
7. Gibbons RV, Vaughn DW. Dengue: an escalating problem. BMJ 2002; 324:1563-6.
8. Suaya JA, Shepard DS, Siqueira JB et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009; 80:846-55.
9. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480-96.
10. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology 1999; 257:1-6.
11. Guzman MG, Kouri G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg 2008; 102:522-3.
12. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-8.
13. Halstead SB. Dengue. Lancet 2007; 370:1644-52.
14. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 2010; 84:4845-50.
15. Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 2002; 76:9877-87.
16. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004; 16:1201-10.
17. Barcelos LS, Coelho AM, Russo RC et al. Role of the chemokines CCL3/MIP-1α and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. Microvasc Res 2009; 78:148-54.
18. Weiss ID, Shoham H, Wald O et al. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions. Cytokine 2011; 54:249-57.
19. Gao JL, Kuhns DB, Tiffany HL et al. Structure and functional expression of the human macrophage inflammatory protein 1α/RANTES receptor. J Exp Med 1993; 177:1421-7.
20. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8.
21. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
22. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009; 4:131-5.
23. Olbrich H, Proudfoot AE, Oppermann M. Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5). J Leukoc Biol 1999; 65:281-5.
24. Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-2.
25. Proudfoot AE, Power CA, Hoogewerf AJ et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996; 271:2599-603.
26. Wells TN, Proudfoot AE, Power CA. Chemokine receptors and their role in leukocyte activation. Immunol Lett 1999; 65:35-40.
27. Shahrara S, Proudfoot AE, Woods JM et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005; 52:1907-19.
28. Repeke CE, Ferreira SB Jr, Vieira AE et al. Dose-response met-RANTES treatment of experimental periodontitis: a narrow edge between the disease severity attenuation and infection control. PLoS One 2011; 6:e22526.
29. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, Lundkvist A, Svensson L. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-9.
30. Glass WG, McDermott DH, Lim JK et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
31. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-98.
32. Bozza FA, Cruz OG, Zagne SM et al. Multiplex cytokine profile from dengue patients: MIP-1β and IFN-γ as predictive factors for severity. BMC Infect Dis 2008; 8:86.
33. de-Oliveira-Pinto LM, Marinho CF, Povoa TF et al. Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever. PLoS One 2012; 7:e38527.
34. Sierra B, Perez AB, Garcia G, Aguirre E, Alvarez M, Gonzalez D, Guzman MG. Role of CC chemokine receptor 1 and two of its ligands in human dengue infection. Three approaches under the Cuban situation. Microbes Infect 2014; 16:40-50.
35. Guabiraba R, Marques RE, Besnard AG, Fagundes CT, Souza DG, Ryffel B, Teixeira MM. Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice. PLoS One 2010; 5:e15680.
36. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 2003; 35:33-42.
37. St John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, Vasudevan SG, Abraham SN. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci U S A 2011; 108:9190-5.
38. Sierra B, Perez AB, Vogt K et al. MCP-1 and MIP-1α expression in a model resembling early immune response to dengue. Cytokine 2010; 52:175-83.
39. Guabiraba R, Besnard AG, Marques RE et al. IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection. Eur J Immunol 2013; 43:1529-44.
40. Le Sommer C, Barrows NJ, Bradrick SS, Pearson JL, Garcia-Blanco MA. G protein-coupled receptor kinase 2 promotes flaviviridae entry and replication. PLoS Negl Trop Dis 2012; 6:e1820.
41. Costa VV, Fagundes CT, Valadao DF et al. A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-γ in host resistance to infection. PLoS Negl Trop Dis 2012; 6:e1663.
42. Souza DG, Fagundes CT, Sousa LP et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A 2009; 106:14138-43.
43. Assuncao-Miranda I, Amaral FA, Bozza FA et al. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 2010; 24:218-28.
44. Wu SJ, Grouard-Vogel G, Sun W et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816-20.
45. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004; 36:35-8.
46. Brinton MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 2002; 56:371-402.
47. Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara A. Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 2009; 5:318-28.
48. Longden J, Cooke EL, Hill SJ. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells. Br J Pharmacol 2008; 153:1513-27.
49. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 2008; 4:e17.
50. Tassaneetrithep B, Burgess TH, Granelli-Piperno A et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197:823-9.
51. Chen ST, Lin YL, Huang MT et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008; 453:672-6.
52. Renneson J, Guabiraba R, Maillet I et al. A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection. Am J Pathol 2011; 179:1872-83.
53. Guabiraba R, Ryffel B. Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. Immunology 2014; 141:143-56.
54. Larena M, Regner M, Lobigs M. The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS One 2012; 7:e44834.
55. Solomon T, Dung NM, Vaughn DW et al. Neurological manifestations of dengue infection. Lancet 2000; 355:1053-9.
56. Brestovac B, Halicki LA, Harris RP, Sampson I, Speers DJ, Mamotte C, Williams D. Primary acute dengue and the deletion in chemokine receptor 5 (CCR5δ32). Microbes Infect 2014; 16:518-21.
57. Malavige GN, Ogg GS. T cell responses in dengue viral infections. J Clin Virol 2013; 58:605-11.
58. Acosta EG, Castilla V, Damonte EB. Differential requirements in endocytic trafficking for penetration of dengue virus. PLoS One 2012; 7:e44835.
59. Deiva K, Khiati A, Hery C, Salim H, Leclerc P, Horellou P, Tardieu M. CCR5-, DC-SIGN-dependent endocytosis and delayed reverse transcription after human immunodeficiency virus type 1 infection in human astrocytes. AIDS Res Hum Retroviruses 2006; 22:1152-61.
60. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J 1997; 16:4606-16.
61. Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 1999; 274:32478-85.
62. Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets 2013; 17:1439-60.